WO2001087862A3 - Biologically active 4h-benzo[1,4]oxazin-3-ones - Google Patents

Biologically active 4h-benzo[1,4]oxazin-3-ones Download PDF

Info

Publication number
WO2001087862A3
WO2001087862A3 PCT/US2001/015383 US0115383W WO0187862A3 WO 2001087862 A3 WO2001087862 A3 WO 2001087862A3 US 0115383 W US0115383 W US 0115383W WO 0187862 A3 WO0187862 A3 WO 0187862A3
Authority
WO
WIPO (PCT)
Prior art keywords
oxazin
benzo
ones
biologically active
pparη
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/015383
Other languages
French (fr)
Other versions
WO2001087862A2 (en
Inventor
Thomas P Burris
Donald W Combs
Philip J Rybczynski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Priority to AU2001263083A priority Critical patent/AU2001263083A1/en
Priority to DE60129123T priority patent/DE60129123T2/en
Priority to DK01937335T priority patent/DK1280784T3/en
Priority to EP01937335A priority patent/EP1280784B1/en
Publication of WO2001087862A2 publication Critical patent/WO2001087862A2/en
Publication of WO2001087862A3 publication Critical patent/WO2001087862A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/6533—Six-membered rings
    • C07F9/65335—Six-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention is directed to 4h-benzo[1,4]oxazin-3-ones useful as peroxisome proliferator activated receptor gamma (PPARη) agonists or antagonists. Pharmaceutical compositions comprising compounds of the present invention and methods of treating conditions such as NIDDM and obesity are also disclosed.
PCT/US2001/015383 2000-05-12 2001-05-11 Biologically active 4h-benzo[1,4]oxazin-3-ones Ceased WO2001087862A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001263083A AU2001263083A1 (en) 2000-05-12 2001-05-11 Biologically active 4h-benzo(1,4)oxazin-3-ones
DE60129123T DE60129123T2 (en) 2000-05-12 2001-05-11 BIOLOGICALLY ACTIVE 4H-BENZO1,40OXAZIN-3-ONE
DK01937335T DK1280784T3 (en) 2000-05-12 2001-05-11 Biologically active 4H-benzo [1,4] oxazin-3-ones
EP01937335A EP1280784B1 (en) 2000-05-12 2001-05-11 Biologically active 4h-benzo 1,4|oxazin-3-ones

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20386000P 2000-05-12 2000-05-12
US60/203,860 2000-05-12
US09/854,302 2001-05-11
US09/854,302 US6555536B2 (en) 2000-05-12 2001-05-11 Biologically active 4H-benzo [1,4]oxazin-3-ones

Publications (2)

Publication Number Publication Date
WO2001087862A2 WO2001087862A2 (en) 2001-11-22
WO2001087862A3 true WO2001087862A3 (en) 2002-05-30

Family

ID=26898967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/015383 Ceased WO2001087862A2 (en) 2000-05-12 2001-05-11 Biologically active 4h-benzo[1,4]oxazin-3-ones

Country Status (12)

Country Link
US (1) US6555536B2 (en)
EP (1) EP1280784B1 (en)
AR (1) AR033375A1 (en)
AT (1) ATE365725T1 (en)
AU (1) AU2001263083A1 (en)
CY (1) CY1106863T1 (en)
DE (1) DE60129123T2 (en)
DK (1) DK1280784T3 (en)
ES (1) ES2288957T3 (en)
MY (1) MY141659A (en)
PT (1) PT1280784E (en)
WO (1) WO2001087862A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US7601841B2 (en) 2000-06-28 2009-10-13 Amgen Inc. Quinolinyl and benzothiazolyl modulators

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6908908B2 (en) * 2000-05-12 2005-06-21 Ortho-Mcneil Pharmaceutical, Inc. Biologically active 4H-benzo [1,4] oxazin-3-ones
KR100965201B1 (en) * 2001-06-12 2010-06-24 웰스테트 테라퓨틱스 코포레이션 Compounds for the treatment of metabolic diseases
AU2003282920A1 (en) 2002-10-04 2004-05-04 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US20080051418A1 (en) * 2004-11-26 2008-02-28 Tsuyoshi Maekawa Arylalkanoic Acid Derivative
US20100227901A1 (en) * 2006-02-28 2010-09-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
KR20090066289A (en) 2006-09-08 2009-06-23 로드아일랜드하스피틀 Treatment, prevention and retrograde alcohol-induced brain disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) * 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1996004260A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
WO1997017333A1 (en) * 1995-11-07 1997-05-15 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
WO1997028167A1 (en) * 1996-01-30 1997-08-07 Ortho Pharmaceutical Corporation 2-substituted amino and thio alkyl benzoxazine antimicrobial agents
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0912575A (en) * 1995-06-28 1997-01-14 Sankyo Co Ltd Benzoxazine and benzothiazine derivative

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019702A1 (en) * 1990-06-14 1991-12-26 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1996004260A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pyridine derivatives useful in the treatment of the type ii diabetes
WO1997017333A1 (en) * 1995-11-07 1997-05-15 Ortho Pharmaceutical Corporation Benzoxazine antimicrobial agents
WO1997028167A1 (en) * 1996-01-30 1997-08-07 Ortho Pharmaceutical Corporation 2-substituted amino and thio alkyl benzoxazine antimicrobial agents
WO1999020614A1 (en) * 1998-05-27 1999-04-29 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601841B2 (en) 2000-06-28 2009-10-13 Amgen Inc. Quinolinyl and benzothiazolyl modulators
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound

Also Published As

Publication number Publication date
DE60129123T2 (en) 2008-02-28
DK1280784T3 (en) 2007-10-29
EP1280784B1 (en) 2007-06-27
PT1280784E (en) 2007-09-03
US6555536B2 (en) 2003-04-29
WO2001087862A2 (en) 2001-11-22
US20020165228A1 (en) 2002-11-07
MY141659A (en) 2010-05-31
ATE365725T1 (en) 2007-07-15
ES2288957T3 (en) 2008-02-01
AR033375A1 (en) 2003-12-17
AU2001263083A1 (en) 2001-11-26
EP1280784A2 (en) 2003-02-05
CY1106863T1 (en) 2012-09-26
DE60129123D1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
CA2522220A1 (en) Cgrp receptor antagonists
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
ATE286500T1 (en) 1,2,3,4-TETRAHYDROISOCINOLINE DERIVATIVES
PT1073470E (en) Pharmaceutical compositions containing active compounds capable of improving the absorption of active ingredients
WO2002076979A8 (en) 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
WO1999063999A8 (en) H1-histamine receptor antagonists
WO2001066564A3 (en) Gamma-secretase inhibitors
EP1268412B8 (en) Sulphonamido-substituted bridged bicycloalkyl derivatives
CA2244785A1 (en) Pentafluorobenzenesulfonamides and analogs
CA2392030A1 (en) Urea compounds having muscarinic receptor antagonist activity
CA2252895A1 (en) Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
MY137535A (en) New pyrrolidinium derivatives
NZ330667A (en) Use of substituted 2,4-imadazolidinedione compounds as analgesics
YU13301A (en) Muscarinic agonists and antagonists
HUP0402486A3 (en) Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
CY1106863T1 (en) 4H-Benzo [1,4] Oxazine-3-One Biologically Active
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
MXPA04001252A (en) Novel benzo-fused heterocycles as endothelin antagonisits.
PL350568A1 (en) N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors
WO2002024665A8 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
WO2000040232A3 (en) Bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
CA2442210A1 (en) Aryl oxime-piperazines useful as ccr5 antagonists
WO2001087860A3 (en) Novel benzoxazinones as peroxisome proliferator activated receptor gamma modulators and method of treatment
CA2299036A1 (en) 4-phenyl-4-heteroarylpiperidine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001937335

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001937335

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001937335

Country of ref document: EP